Compounded Tirzepatide: Cost, Legality, and What to Know

What Is Compounded Tirzepatide?

Pharmaceutical compounding allows pharmacies to prepare customized medication formulations for specific patient needs. During the Mounjaro and Zepbound shortage of 2022–2024, compounding pharmacies began manufacturing tirzepatide independently, sourcing the active pharmaceutical ingredient (API) separately from Eli Lilly.

At its peak, hundreds of telehealth platforms offered compounded tirzepatide, positioning it as a lower-cost pathway to the same active ingredient as Zepbound.

Legal Status in 2025–2026

The FDA declared the tirzepatide shortage resolved in late 2024. This decision is legally significant: FDA regulations permit compounding of drugs that are on the shortage list. When the shortage ends, the legal basis for compounding that drug is substantially narrowed.

Current status:

• 503B outsourcing facilities: Most cannot legally compound tirzepatide following the shortage declaration removal. The FDA has issued guidance accordingly.
• 503A pharmacies: Patient-specific compounding (individual prescriptions) has narrower exemptions that some pharmacies are claiming, but regulatory enforcement is active.
• Enforcement: The FDA has sent warning letters to compounders and some have been ordered to stop. Others continue operating in claimed gray areas.

The situation is materially different from compounded semaglutide at peak: the tirzepatide compounding market is more restricted and more scrutinized as of 2025–2026.

Patients interested in compounded tirzepatide should verify current regulatory status at time of inquiry, as this is an area of active enforcement.

Compounded vs. Branded Tirzepatide

The Better Alternative: LillyDirect Self-Pay Vials

This is the clearest practical guidance for cost-driven patients who were considering compounded tirzepatide: Eli Lilly sells FDA-approved tirzepatide directly to patients via LillyDirect.com at significantly reduced prices.

• Price: $399/month (2.5 mg or 5 mg doses) to $549/month (7.5–15 mg doses)
• Product: The same FDA-approved tirzepatide — not compounded, fully validated
• Format: Single-dose vials (patient draws and injects) — same format as most compounders
• Availability: Requires cash payment; does not go through insurance

For patients who want tirzepatide at lower cost without the legal and safety uncertainty of compounding, this is the superior option. The price difference between LillyDirect and most compounders has narrowed significantly since Lilly introduced this program.

Safety Considerations for Compounded Options

If patients pursue compounded tirzepatide despite the regulatory landscape:

Purity and potency variability. Compounders source API from various suppliers with variable quality controls. The FDA has documented compounded GLP-1 products with inaccurate dosing and non-standard additives in inspection reports.

Formulation differences. Some compounders use tirzepatide salts or modified forms not present in Eli Lilly's approved product. Equivalence is not established by clinical data.

Dosing errors. Branded Zepbound pens have preset doses difficult to miscalculate. Patient-drawn vials introduce more dosing error risk. At tirzepatide's potency, over- or under-dosing has real consequences.

How to evaluate a compounder (if pursuing this route):

• Prefer 503B outsourcing facilities over 503A pharmacies (higher regulatory standards)
• Request certificates of analysis (COA) from third-party testing labs
• Verify prescriber involvement and monitoring
• Understand you're accepting legal and safety uncertainty

Insurance Coverage and Savings Cards

Before considering compounding for cost reasons, patients should exhaust standard options:

Eli Lilly savings cards: Commercially insured patients may pay as little as $25/month for Mounjaro or Zepbound with Lilly's savings card programs.

Insurance coverage: Zepbound (obesity indication) is covered by a growing number of commercial plans. Mounjaro (diabetes indication) has broader formulary coverage. Prior authorization processes vary by plan.

Patient assistance programs: Uninsured patients with qualifying income may receive Zepbound at no cost through Lilly's patient assistance program.

Exhausting these options before turning to compounding is advisable — the total cost may be lower and the regulatory situation cleaner.

Bottom Line

Compounded tirzepatide occupies a legally restricted and safety-uncertain space in 2025–2026. The FDA declared the tirzepatide shortage over, removing the primary legal basis for most compounding. For cost-driven patients, Eli Lilly's official LillyDirect self-pay vials ($399–549/month) represent a meaningfully better option — FDA-approved, validated purity, comparable cost to many compounders. Patients who pursue compounded tirzepatide despite this should use 503B facilities, request third-party COAs, and work with a licensed prescriber.

Sources

• Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity," NEJM, 2022
• FDA, "FDA alerts patients and health care professionals about risks of compounded GLP-1 drugs," FDA.gov, 2024
• FDA, "Compounding and the FDA: Questions and Answers," FDA.gov
• Eli Lilly, Zepbound Prescribing Information, 2023